• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ANEB

    Anebulo Pharmaceuticals Inc.

    Subscribe to $ANEB
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: anebulo.com

    Recent Analyst Ratings for Anebulo Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Anebulo Pharmaceuticals Inc. SEC Filings

    See more
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/15/25 4:15:33 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/11/25 7:04:26 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      4/4/25 6:09:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Anebulo Pharmaceuticals Inc.

      SCHEDULE 13G - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

      3/17/25 4:51:40 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Anebulo Pharmaceuticals Inc.

      DEF 14A - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      3/6/25 7:00:29 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Anebulo Pharmaceuticals Inc.

      424B5 - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      3/3/25 4:00:20 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Anebulo Pharmaceuticals Inc.

      EFFECT - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      3/3/25 12:15:12 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Anebulo Pharmaceuticals Inc.

      SCHEDULE 13D/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)

      2/27/25 7:41:23 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Anebulo Pharmaceuticals Inc.

      PRE 14A - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      2/24/25 5:21:43 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

      2/24/25 5:18:24 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Anebulo Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      12/26/24 4:15:08 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Anebulo Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lawler Joseph F.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:39 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shah Bimal R.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:38 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Cundy Kenneth C

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:37 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lin Kenneth

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:33 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aryeh Jason

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:36 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kupchyk Areta

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:31 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director English Aron R.

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:32 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Cunningham, Richard Anthony

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:34 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Calloway Nathaniel

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      4/7/25 9:41:31 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

      4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

      12/26/24 4:15:08 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Anebulo Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing. FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediat

      2/14/25 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children Anebu

      12/23/24 9:15:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2024, and recent updates. First Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo announced it has been awarded the first tranche of a two-year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), under award number 1U01DA059995-01. With the support of NIDA, Anebulo aims to complete IND-enabling

      11/13/24 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended June 30, 2024, and recent updates. Fourth Quarter Fiscal Year 2024 and Subsequent Highlights: Anebulo announced it has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH") With the support of NIDA, Anebulo aims to complete IND-enabling activities and the scale up of

      9/25/24 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to support the development of intravenous selonabant, for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression in children. The grant comes in the form of two tranches with the initial award of $0.9 million and sub

      7/22/24 7:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2024, and recent updates. Third Quarter Fiscal Year 2024 and Subsequent Highlights: Anebulo prioritizes development of selonabant IV formulation for unintentional cannabis poisoning in children in response to the growing medical need and impending change in DEA scheduling On April 30, 2024, the United States Department of Justice

      5/15/24 1:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2023, and recent updates. Second Quarter Fiscal Year 2024 and Subsequent Highlights: Richie Cunningham announced as Chief Executive Officer United States Adopted Names (USAN) adopted selonabant as the generic name for ANEB-001 Advancing selonabant IV formulation as a second product Secured a credit facility of up to $10 million Bimal Shah announced as Board Member "Anebu

      2/13/24 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2023, and recent updates. First Quarter Fiscal Year 2024 and Subsequent Highlights: Richie Cunningham announced as Chief Executive Officer and Board Member Positive Type B meeting with the United States Food and Drug Administration (FDA), focusing on finalizing our registrational study designs The Company presented at two major scientific meetings: the American College of Emergency

      11/14/23 4:05:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Third Quarter 2023 Financial Results

      Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

      11/8/23 4:01:00 PM ET
      $AMGN
      $ANEB
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

      10/6/23 4:06:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Anebulo Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

      10/6/23 4:06:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

      Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

      3/8/23 8:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

      11/1/22 4:00:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company. Dr. Cundy is a highly respected scientist having innovated and developed multiple therapeutics throughout his career. "I am thrilled to welcome Ken to the Anebulo team, his expertise in drug development comes at an opportune time for the Company as we advance ANEB-001 through human clinical trials for acute cannabinoid intoxication," said Simon Allen, Chi

      5/24/22 4:00:00 PM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

      Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately. In this position, Mr. Anderson will report directly to Rex Merchant, Anebulo's Chief Financial Officer. Mr. Anderson will be responsible for Anebulo's global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of informati

      1/6/22 7:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture

      Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. "Tenaya is at an important inflection point in our growth and maturity. We are now a public company with more than 100 employees who represent our commitment to internalize critical capabilities, including cGMP manufacturing and clinical development," said Faraz Ali, CEO of Tenaya. "Both Karah and Joanna are strong leaders who bring highly relevant strategic

      12/22/21 4:05:00 PM ET
      $ANEB
      $EOLS
      $TNYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    Anebulo Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Ligand Reports Third Quarter 2023 Financial Results

      Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

      11/8/23 4:01:00 PM ET
      $AMGN
      $ANEB
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Reports First Quarter 2023 Financial Results

      2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

      5/4/23 4:01:00 PM ET
      $ANEB
      $LGND
      $NOVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

      Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

      7/5/22 6:00:00 AM ET
      $ANEB
      Biotechnology: Pharmaceutical Preparations
      Health Care